Cagrilintide

Cagrilintide – Research Peptide

Long-Acting Amylin Analogue for Appetite Regulation, Satiety Signaling & Metabolic Research

Cagrilintide is a synthetic, long-acting amylin analogue developed for scientific and clinical investigation of appetite regulation, satiety signaling, food intake and body-weight-related metabolic pathways.

Derived from the biological activity of the pancreatic hormone amylin, cagrilintide has been designed to provide prolonged pharmacological activity through structural modifications that improve its stability and duration of action.

Amylin is a naturally occurring peptide hormone co-secreted with insulin by pancreatic beta cells. It participates in the regulation of food intake, gastric emptying and postprandial metabolic responses.

Cagrilintide has attracted substantial scientific interest because it targets amylin-associated signaling pathways that differ from those of glucagon-like peptide-1 (GLP-1) receptor agonists.

Its development has included clinical research as an individual investigational compound and in combination with semaglutide, a GLP-1 receptor agonist.

The combination of cagrilintide and semaglutide is commonly referred to as CagriSema.

These investigations have expanded scientific understanding of how complementary hormonal signaling pathways influence appetite, energy balance and metabolic regulation.

ICAME Pharmacy Cagrilintide is intended strictly for laboratory research and development purposes. It is not intended for human or veterinary use.

What Is Cagrilintide?

Cagrilintide is a modified peptide analogue of amylin, also known as islet amyloid polypeptide (IAPP).

Natural amylin is a 37-amino-acid hormone produced primarily by pancreatic beta cells.

It is released alongside insulin in response to nutrient intake and participates in the regulation of several physiological processes.

These include:

• Satiety signaling

• Food intake regulation

• Gastric emptying

• Postprandial glucose regulation

• Brain–gut communication

• Energy homeostasis

Cagrilintide was developed to reproduce selected biological activities of amylin while providing a substantially longer duration of action.

Its molecular design includes modifications intended to improve peptide stability and prolong systemic exposure.

These properties have made cagrilintide an important investigational compound in metabolic and appetite-regulation research.

Cagrilintide and the Amylin Hormone

Amylin is an important component of the body's hormonal response to food intake.

It is secreted by pancreatic beta cells together with insulin, although the two hormones have different physiological roles.

Insulin primarily participates in glucose regulation and nutrient storage.

Amylin contributes to postprandial metabolic regulation through pathways involving the gastrointestinal system and central nervous system.

Simplified Biological Pathway

Food Intake

↓

Pancreatic Beta-Cell Activity

↓

Amylin Secretion

↓

Amylin Receptor Signaling

↓

Brainstem & Metabolic Pathways

↓

Satiety and Food Intake Regulation

Cagrilintide has been developed to investigate and therapeutically target aspects of this amylin-associated signaling system.

Proposed Mechanism of Action

Cagrilintide acts through receptors associated with the amylin and calcitonin receptor families.

Amylin receptors are formed through interactions between the calcitonin receptor (CTR) and receptor activity-modifying proteins known as RAMPs.

These receptor complexes participate in signaling pathways relevant to appetite regulation and metabolic physiology.

The area postrema, a region of the brainstem involved in detecting circulating physiological signals, is considered an important site of amylin-associated activity.

Simplified Research Mechanism

Cagrilintide

↓

Amylin / Calcitonin Receptor-Associated Signaling

↓

Brainstem Signaling Networks

↓

Satiety-Related Neural Pathways

↓

Food Intake & Energy Balance Regulation

The precise contributions of different receptor subtypes and neural circuits remain active areas of scientific investigation.

Cagrilintide should therefore not be described as acting exclusively through one receptor subtype or a single neural pathway.

Cagrilintide and Amylin Receptor Biology

Amylin receptor signaling is an important area of contemporary metabolic research.

Functional amylin receptor complexes are formed when the calcitonin receptor interacts with receptor activity-modifying proteins.

The principal complexes are commonly described as:

AMY1 – CTR + RAMP1

AMY2 – CTR + RAMP2

AMY3 – CTR + RAMP3

These receptor complexes can exhibit different pharmacological properties.

Research involving cagrilintide is relevant to understanding:

• Amylin receptor pharmacology

• Calcitonin receptor signaling

• RAMP-associated receptor modulation

• Peptide–receptor interactions

• Central appetite-regulation pathways

• Receptor selectivity and signaling responses

Understanding these receptor systems is essential for interpreting the pharmacology of long-acting amylin analogues.

Cagrilintide and Appetite Regulation

Appetite regulation involves communication between the gastrointestinal tract, pancreas, brainstem and hypothalamus.

Numerous hormones participate in this network, including:

Amylin

GLP-1

Ghrelin

Leptin

Insulin

Peptide YY

These hormones influence different aspects of hunger, satiety and metabolic signaling.

Cagrilintide has been investigated because amylin-associated pathways contribute to the regulation of food intake.

Clinical studies have demonstrated that pharmacological modulation of these pathways can influence body-weight-related outcomes.

However, the results of clinical investigations involving regulated trial formulations should not be interpreted as evidence that laboratory-grade cagrilintide products are suitable for human use.

Cagrilintide and Satiety Signaling

Satiety refers to the physiological processes that contribute to the sensation of fullness and the termination or suppression of further food intake.

Amylin participates in satiety signaling through neural pathways involving the brainstem and interconnected appetite-regulation networks.

Cagrilintide has been developed to investigate prolonged activation of these pathways.

Potential research areas include:

Meal termination signaling

Postprandial satiety

Food intake regulation

Brainstem receptor activity

Hormonal appetite signaling

Energy balance

These pathways are particularly relevant to studies examining the interaction between peripheral metabolic hormones and central nervous system responses.

Cagrilintide and the Central Nervous System

The central nervous system integrates hormonal, neural and nutrient-related signals to coordinate energy balance.

Amylin-associated signaling involves the area postrema and related brainstem structures.

These pathways interact with broader neural networks involved in appetite and metabolic regulation.

Cagrilintide research has therefore generated interest in:

• Brainstem signaling

• Area postrema biology

• Neural regulation of satiety

• Hormonal signaling in the CNS

• Brain–gut communication

• Energy homeostasis

The specific neural mechanisms underlying the clinical effects of cagrilintide are still being investigated.

Cagrilintide and Gastric Emptying Research

Natural amylin contributes to the regulation of gastric emptying.

Gastric emptying is the process through which stomach contents pass into the small intestine.

Its regulation influences nutrient delivery and postprandial metabolic responses.

Amylin-associated pathways have therefore been investigated in connection with:

Gastric motility

Nutrient absorption timing

Postprandial signaling

Glucose regulation

Satiety

The extent to which individual effects of cagrilintide on gastric physiology contribute to its overall clinical activity requires careful interpretation.

Cagrilintide should not be assumed to reproduce every physiological effect of native amylin identically.

Cagrilintide and Metabolic Research

Metabolic regulation depends on coordinated communication between the brain, pancreas, gastrointestinal tract and peripheral tissues.

Cagrilintide is relevant to research examining this communication because it targets hormonal pathways involved in appetite and energy balance.

Areas of scientific interest include:

Energy intake regulation

Body-weight-associated physiology

Postprandial hormonal signaling

Metabolic homeostasis

Appetite-related neural pathways

Hormonal interactions

Cagrilintide has also been investigated in people with obesity and type 2 diabetes, providing clinical research data on body weight and selected metabolic outcomes.

Cagrilintide and GLP-1 Research

One of the most important areas of cagrilintide research involves its combination with GLP-1 receptor agonists.

GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone involved in glucose regulation, appetite signaling and gastrointestinal physiology.

GLP-1 receptor agonists and amylin analogues act through different, partly complementary biological mechanisms.

This has led researchers to investigate whether simultaneous modulation of both pathways produces effects that differ from either approach alone.

Amylin and GLP-1 Research Pathways

Cagrilintide

→ Amylin / Calcitonin Receptor-Associated Signaling

Semaglutide

→ GLP-1 Receptor Signaling

↓

Complementary Appetite and Metabolic Pathways

↓

Clinical Investigation of Food Intake and Body-Weight Outcomes

The scientific rationale for combining these mechanisms is based on their distinct receptor pharmacology and partly complementary physiological effects.

What Is CagriSema?

CagriSema is the development name for a fixed-dose investigational combination of cagrilintide and semaglutide.

The combination has been investigated in a clinical development program known as REDEFINE.

CagriSema research has examined the potential benefits and risks of combining long-acting amylin receptor-associated activity with GLP-1 receptor agonism.

Importantly, CagriSema is a specific pharmaceutical development program.

A research-grade cagrilintide product is not CagriSema, and combining independently sourced research compounds does not create an equivalent pharmaceutical product.

Clinical results from CagriSema studies must not be presented as the demonstrated efficacy or safety of ICAME Pharmacy Cagrilintide.

Cagrilintide Monotherapy: Phase 2 Research

A randomized, double-blind, placebo-controlled phase 2 study published in The Lancet in 2021 investigated cagrilintide in adults with overweight or obesity.

The trial evaluated different cagrilintide treatment groups and included placebo and an active comparator.

At 26 weeks, the study reported estimated mean body-weight reductions of approximately 6.0% to 10.8% across the investigated cagrilintide groups, compared with approximately 3.0% in the placebo group, using the trial-product estimand.

The most frequently reported adverse events included gastrointestinal symptoms, particularly nausea, along with constipation, diarrhea and administration-site reactions.

These findings supported further clinical investigation of cagrilintide as a long-acting amylin analogue.

However, the results relate to controlled clinical trial formulations and should not be interpreted as evidence of safety or efficacy for research-grade products.

Cagrilintide and the REDEFINE 1 Trial

The phase 3 REDEFINE 1 study investigated cagrilintide combined with semaglutide in adults with overweight or obesity without diabetes.

The randomized study included more than 3,400 participants and evaluated body-weight outcomes over 68 weeks.

Using the treatment-policy estimand, the estimated mean percentage change in body weight was:

Cagrilintide + Semaglutide: −20.4%

Placebo: −3.0%

The study demonstrated substantial body-weight reductions with the investigated combination.

Gastrointestinal adverse events were common and included nausea, vomiting, diarrhea, constipation and abdominal pain.

These results are important to the clinical development of combined amylin and GLP-1 receptor-associated therapies.

They do not establish equivalent effects for cagrilintide alone or for research-grade cagrilintide products.

Cagrilintide and Type 2 Diabetes Research

The REDEFINE 2 clinical trial investigated the cagrilintide–semaglutide combination in adults with overweight or obesity and type 2 diabetes.

The trial evaluated body-weight and metabolic outcomes over 68 weeks.

The estimated mean percentage change in body weight was:

Cagrilintide + Semaglutide: −13.7%

Placebo: −3.4%

The study also investigated glycemic outcomes, including glycated hemoglobin.

These results contributed to understanding the clinical effects of combined amylin and GLP-1 receptor-associated signaling in people with type 2 diabetes.

However, findings from combination treatment cannot be attributed exclusively to cagrilintide.

Cagrilintide and Energy Homeostasis

Energy homeostasis refers to the regulation of energy intake, expenditure and storage.

The central nervous system integrates signals from multiple hormones and nutrient-sensing pathways to coordinate these processes.

Cagrilintide research is particularly relevant to the regulation of energy intake through satiety-associated pathways.

Potential areas of investigation include:

• Hormonal appetite regulation

• Energy intake

• Central nervous system signaling

• Meal-related satiety

• Brainstem metabolic pathways

• Long-acting peptide pharmacology

• Combined hormonal signaling

Cagrilintide should not be described as a proven direct fat-burning compound or a general stimulant of energy expenditure.

Its principal investigated mechanism is associated with amylin-related appetite and satiety signaling.

Cagrilintide vs. Semaglutide

Although both compounds have been investigated in metabolic research, their pharmacological classifications differ.

The two compounds are not interchangeable.

Their different receptor mechanisms are central to the scientific rationale behind combination research.

Cagrilintide and Long-Acting Peptide Design

Native amylin presents challenges for pharmaceutical development because of its physicochemical properties, including a tendency toward aggregation.

Cagrilintide was developed through peptide engineering approaches designed to improve stability and extend pharmacological activity.

Its design includes structural modifications and lipidation.

These modifications are relevant to:

Peptide stability

Pharmacokinetic behavior

Duration of exposure

Receptor pharmacology

Structure–activity relationships

This makes cagrilintide interesting not only for metabolic research but also for the broader study of long-acting peptide drug design.

Potential Research Applications

Cagrilintide may be of interest in controlled scientific investigations involving:

• Amylin receptor biology

• Calcitonin receptor signaling

• RAMP-associated receptor complexes

• Appetite regulation

• Satiety signaling

• Food intake research

• Brainstem signaling

• Area postrema biology

• Central nervous system metabolism

• Energy homeostasis

• Brain–gut communication

• Gastric physiology

• Postprandial hormonal regulation

• Metabolic research

• Obesity-related biological pathways

• GLP-1 and amylin pathway interactions

• Peptide structure–activity relationships

• Long-acting peptide pharmacology

• Experimental receptor pharmacology

The scientific importance of cagrilintide lies in its ability to support investigation of amylin-associated pathways and their interactions with broader metabolic signaling networks.

Current Clinical Research and Limitations

Cagrilintide has been evaluated in controlled human clinical trials, both individually and in combination with semaglutide.

Clinical studies have demonstrated measurable effects on body-weight-related outcomes in defined trial populations.

However, several important distinctions must be maintained.

First, findings from a specific pharmaceutical formulation cannot automatically be applied to a research-grade material.

Second, combination-trial outcomes cannot be attributed solely to cagrilintide.

Third, clinical effectiveness and tolerability in trial populations do not establish the safety of unapproved or independently sourced products.

Fourth, long-term outcomes, receptor-specific mechanisms and comparative clinical benefits remain important areas of ongoing investigation.

Accordingly, research-grade cagrilintide should not be marketed as an approved weight-management treatment.

Cagrilintide Research Overview

Compound: Cagrilintide

Compound Classification: Synthetic Long-Acting Amylin Analogue

Parent Hormone: Amylin / Islet Amyloid Polypeptide (IAPP)

Principal Research Targets: Amylin and Calcitonin Receptor-Associated Pathways

Primary Research Areas: Appetite Regulation / Satiety Signaling / Energy Homeostasis

Additional Research Areas: Brainstem Signaling / Metabolic Research / Long-Acting Peptide Pharmacology

Combination Research: Cagrilintide + Semaglutide (CagriSema)

Product Information

Product Name: Cagrilintide

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Long-Acting Amylin Analogue

Research Area: Amylin Receptor Biology / Appetite Signaling / Metabolic Research

Intended Use: Laboratory Research & Development Only

The exact peptide sequence, molecular specifications and chemical form of the supplied cagrilintide should be verified using the manufacturer's documentation.

Batch-specific information, including purity, analytical methodology, Certificate of Analysis (COA), batch/lot identification and validated storage conditions, should be provided according to the documentation associated with each individual production batch.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, weight-management, appetite-suppression or performance-enhancing purposes. Not for direct administration to humans or animals.

Cagrilintide is a pharmacologically active investigational peptide.

Clinical research findings involving pharmaceutical cagrilintide formulations or CagriSema should not be interpreted as evidence of safety, efficacy or pharmaceutical equivalence for ICAME Pharmacy research products.

Information presented on this page is intended solely for scientific and educational purposes and should not be interpreted as medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to contemporary areas of peptide science, molecular biology, metabolic research, receptor pharmacology, neuroendocrine signaling and experimental life sciences.

Product information is presented with an emphasis on responsible research use, scientific transparency, clear product identification and professional research applications.

For batch-specific documentation, analytical information and product inquiries, please contact ICAME Pharmacy.